NewAmsterdam Pharma (NAMS) FCF Margin (2023 - 2025)
Historic FCF Margin for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to 9428.45%.
- NewAmsterdam Pharma's FCF Margin fell 93852400.0% to 9428.45% in Q3 2025 from the same period last year, while for Sep 2025 it was 410.12%, marking a year-over-year increase of 507600.0%. This contributed to the annual value of 349.49% for FY2024, which is 6529400.0% up from last year.
- Per NewAmsterdam Pharma's latest filing, its FCF Margin stood at 9428.45% for Q3 2025, which was down 93852400.0% from 197.23% recorded in Q2 2025.
- Over the past 5 years, NewAmsterdam Pharma's FCF Margin peaked at 43.2% during Q3 2024, and registered a low of 9428.45% during Q3 2025.
- In the last 3 years, NewAmsterdam Pharma's FCF Margin had a median value of 1411.35% in 2023 and averaged 2357.61%.
- As far as peak fluctuations go, NewAmsterdam Pharma's FCF Margin soared by 38256900bps in 2024, and later crashed by -93852400bps in 2025.
- Quarter analysis of 3 years shows NewAmsterdam Pharma's FCF Margin stood at 4119.18% in 2023, then skyrocketed by 93bps to 293.49% in 2024, then plummeted by -3113bps to 9428.45% in 2025.
- Its last three reported values are 9428.45% in Q3 2025, 197.23% for Q2 2025, and 1225.12% during Q1 2025.